Precision Neuroscience is an Invasive Cortical Implants company founded in 2021 and based in New York, United States. It has raised $180M in total funding, most recently a Series C in 2024 at a $500M valuation.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Dec 16, 2024 | Series C | $102M | $500M | General Equity Holdings |
| Jan 25, 2023 | Series B | $41M | — |
| Forepont Capital Partners |
| May 1, 2021 | Series A | $12M | — | Steadview Capital |

An analysis piece finds that BCI startups' use of 'minimally invasive' is fuzzy and inconsistent.

Brain implant restores movement and touch in a paralysed man.

Precision Neuroscience CEO Michael Mager discusses the company's technology and strategy in an interview.
A thin-film flexible electrode array placed on the brain's surface (electrocorticography) via a minimally-invasive slot craniotomy, enabling high-resolution neural recording across thousands of electrode sites without penetrating brain tissue. Received FDA 510(k) clearance in April 2025 for recording, monitoring, and stimulation during temporary implantation (up to 30 days). Already tested in temporary intraoperative placements across multiple human neurosurgery patients.
8 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗